MedTrace Logo

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

NCT02387853 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2025-03-10

Study results available
· View outcomes & findings →

Summary

An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

LEO 90100

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • M Seyger, MD · UMC St Radboud

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2018-03-28
Completion
2018-03-28

Countries

  • United States
  • Netherlands
  • Poland
  • Romania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02387853 on ClinicalTrials.gov